CAS NO: | 54-21-7 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
500mg | 电议 |
10 g | 电议 |
50 g | 电议 |
> 100 g | 电议 |
生物活性 |
Sodium Salicylate (Salicylic acid sodium salt) inhibits cyclo-oxygenase-2 (COX-2) activity independently of transcription factor (NF-κB) activation[1]. Sodium Salicylate is also aS6Kinhibitor.Sodium Salicylate is aNF-κBinhibitor that decreases inflammatory gene expression and improves repair in aged muscle[4]. |
||||||||||||||||
IC50& Target[1][2] |
|
||||||||||||||||
体外研究 (In Vitro) |
Sodium Salicylate is an effective inhibitor of COX-2 activity at concentrations far below those required to inhibit NF-κB (20 mg/mL) activation. Sodium Salicylate inhibits prostaglandin E2release when add together with interleukin 1β for 24 hr with an IC50value of 5 μg/mL, an effect that is independent of NF-κB activation or COX-2 transcription or translation. Sodium Salicylate acutely (30 min) also causes a concentration-dependent inhibition of COX-2 activity measured in the presence of 0, 1, or 10 μM exogenous arachidonic acid. In contrast, when exogenous arachidonic acid is increased to 30 μM, Sodium Salicylate is a very weak inhibitor of COX-2 activity with an IC50of >100 μg/mL. When added together with IL-1β for 24 hr, Sodium Salicylate causes a concentration-dependent inhibition of PGE2release with an apparent IC50value of approximately 5 μg/mL. The ability of Sodium Salicylate to directly inhibit COX-2 activity in A549 cells is tested after a 30-min exposure period, followed by the addition of different concentrations of exogenous arachidonic acid (1, 10, and 30 μM). Sodium Salicylate causes a concentration-dependent inhibition of COX-2 activity in the absence of added arachidonic acid or in the presence of 1 or 10 μM exogenous substrate with an apparent IC50value of approximately 5 μg/mL. However, when the same experiments are performed using 30 μM arachidonic acid, Sodium Salicylate is an ineffective inhibitor of COX-2 activity, with an apparent IC50value of more than 100 μg/mL, and achieves a maximal inhibition of less than 50%[1].
|
||||||||||||||||
体内研究 (In Vivo) |
In C57Bl/6 DIO mice, Salicylate decreases both fasting and postprandial plasma glucose levels. Furthermore, there is a trend to reduce plasma triglyceride levels after Salicylate treatment in C57Bl/6 DIO mice (P=0.059). Salicylate significantly reduces 11β-HSD1 mRNA in omental adipose tissue in C57Bl/6 DIO mice, with a similar trend in mesenteric adipose (P=0.057). In mesenteric adipose of C57Bl/6 DIO mice, Salicylate also reduces 11β-HSD1 enzyme activity[2].
|
||||||||||||||||
Clinical Trial |
|
||||||||||||||||
分子量 |
160.10 |
||||||||||||||||
性状 |
Solid |
||||||||||||||||
Formula |
C7H5NaO3 |
||||||||||||||||
CAS 号 |
54-21-7 |
||||||||||||||||
中文名称 |
水杨酸钠 |
||||||||||||||||
结构分类 |
|
||||||||||||||||
来源 |
|
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
||||||||||||||||
溶解性数据 |
In Vitro:
H2O : ≥ 100 mg/mL(624.61 mM) DMSO : 100 mg/mL(624.61 mM;Need ultrasonic) *"≥" means soluble, but saturation unknown.
配制储备液
*
请根据半岛bd体育手机客户端 在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的半岛bd体育手机客户端 失效。
In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
*
以上所有助溶剂都可在本网站选购。
|